Stockscreener 앱 받기
1.67
6.18%
-0.11
시간 외 거래:
1.67
Black Diamond Therapeutics Inc 주식(BDTX)의 최신 뉴스
Positive week for Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) institutional investors who lost 74% over the past year - Yahoo Finance
A History of Outperforming Analyst Forecasts and Beating the Odds: Black Diamond Therapeutics Inc (BDTX) - Sete News
Black Diamond Therapeutics Inc (BDTX) stock analysis: A comprehensive overview - uspostnews.com
Black Diamond Therapeutics Inc’s Banking’s 100-Day Moving Average at 2.0161: Will the Stock Break Through? - investchronicle.com
Geode Capital Management LLC Has $2.05 Million Holdings in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
Financial Metrics Exploration: Understanding Black Diamond Therapeutics Inc (BDTX) Through Ratios - DWinneX
Black Diamond Therapeutics Inc (BDTX) presents a great opportunity, but the stock is slightly overvalued - uspostnews.com
Head-To-Head Contrast: Avalon GloboCare (NASDAQ:ALBT) and Black Diamond Therapeutics (NASDAQ:BDTX) - Defense World
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares Acquired by Wellington Management Group LLP - Defense World
Raymond James Financial Inc. Purchases New Position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
Sei Investments Co. Purchases Shares of 22,802 Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
BDTX Stock Sees Decline of Approximately -12.66% in Last Five Days - knoxdaily.com
Black Diamond stock hits 52-week low at $1.42 amid challenges - Investing.com India
Black Diamond stock hits 52-week low at $1.42 amid challenges By Investing.com - Investing.com South Africa
Black Diamond Therapeutics Inc [BDTX] stock for 11,997,749 USD was sold by BIOTECH GROWTH N V - knoxdaily.com
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Stock Holdings Raised by Intech Investment Management LLC - The AM Reporter
Bank of New York Mellon Corp Purchases 65,341 Shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
Black Diamond Therapeutics’ Global Licensing Deal with Servier - Global Legal Chronicle
BDTX stock touches 52-week low at $1.59 amid market challenges - Investing.com Australia
Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With Servier - Seeking Alpha
What is Wedbush’s Estimate for BDTX Q1 Earnings? - Defense World
Connor Clark & Lunn Investment Management Ltd. Sells 37,472 Shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
BB Biotech AG Reduces Stake in Black Diamond Therapeutics Inc - GuruFocus
Black Diamond Therapeutic Stock Price, Quotes and Forecasts | NASDAQ:BDTX - Benzinga
Stock Traders Buy High Volume of Call Options on Black Diamond Therapeutics (NASDAQ:BDTX) - Defense World
Growth Stocks To Add to Your Watchlist – March 19th - Defense World
Black Diamond Therapeutics (NASDAQ:BDTX) Earns “Outperform” Rating from Wedbush - Defense World
HC Wainwright Has Bearish Forecast for BDTX Q1 Earnings - Defense World
Black Diamond Therapeutics sees $11.99m stock sale by BB Biotech AG - Investing.com
Growth Stocks To Add to Your WatchlistMarch 19th - MarketBeat
Black Diamond Therapeutics Surge: Savvy Move or Bubble? - timothysykes.com
Black Diamond Gets The Gift Of Time In License Pact With Servier - insights.citeline.com
Servier and Black Diamond enter oncology licensing deal By Investing.com - Investing.com South Africa
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, a Targeted Oncology Therapy - Marketscreener.com
Sector Update: Health Care -March 19, 2025 at 03:43 pm EDT - Marketscreener.com
Black Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Year-High - NewsBreak: Local News & Alerts
This Biotech Is Finding Mid-Week Success Following Licensing Agreement Announcement - The Globe and Mail
Black Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Yea - Asianet Newsable
Black Diamond Therapeutics surges on licensing deal - MSN
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Black Diamond Therapeutics Inks Licensing Pact With French Pharma Firm Servier For Its Early-Stage Cancer Drug Worth Over $700 Million - Benzinga
Black Diamond Therapeutics (BDTX) Stock Jumps After Entering Licensing Deal - Stocks Telegraph
Black Diamond stock surges on licensing deal (BDTX:NASDAQ) - Seeking Alpha
Servier and Black Diamond collaborate on BDTX-4933 - The Pharma Letter
Black Diamond Therapeutics, Servier Sign Global Licensing Deal for BDTX-4933 to Treat Solid Tumors - Marketscreener.com
0.39%
3.66%
자본화:
|
볼륨(24시간):